Since its STAR Market listing seven years ago, Medicilon has delivered resilient growth: steady expansion from 2019 to 2022; cyclical adjustments amid industry headwinds in 2023–2024; performance stabilization and recovery in 2025. In the first three quarters of 2026, the company posted operating revenue of RMB 1.215 billion, up 44.13% YoY, and net profit attributable to parent of RMB 91.9992 million, surging 409.92% YoY and returning to profitability. Quarterly performance continued to improve: Q1 revenue of RMB 365 million with attributable net profit of RMB 15.6154 million; Q2 revenue of RMB 397 million with attributable net profit of RMB 35.9870 million; Q3 revenue of RMB 453 million with attributable net profit of RMB 40.3968 million, achieving both year-on-year and sequential growth.
Order mix shapes short-term results, while core moats determine long-term competitiveness. Over seven years as a public firm, Medicilon has developed three hard-to-replicate core capabilities to build resilience against industry volatility.
One-Stop Platform : Connecting Target to IND to Unlock Synergistic Value
The synergies of this one-stop model are directly reflected in our order structure. In H1 2026, revenue from drug discovery and pharmaceutical development reached RMB 347 million, a 29.42% YoY increase; preclinical service revenue stood at RMB 414 million, rising 52.26% YoY and acting as the key driver of growth. Total new signed orders in H1 2026 reached RMB 1.233 billion, up 104.74% YoY. New preclinical orders amounted to RMB 820 million, jumping 141.63% YoY. Strong uptake of full-package engagements validates the platform’s reliable delivery capacity.
Global Compliance Capabilities : Supporting Multi-Jurisdictional Filings to Expand Overseas Reach
Overseas expansion of Chinese innovative drugs has become a long-term trend. US‑China filings and global synchronized submissions set high standards for CROs on compliance qualifications and cross-acceptance of study data.
Medicilon holds NMPA and OECD GLP accreditations and conducts studies compliant with FDA GLP requirements. In June 2026, our Boston research facility obtained AAALAC International accreditation. A single set of study data can now support regulatory reviews across multiple countries, highlighting our differentiated global compliant delivery capability.
Building on this foundation, Medicilon pursues a global market strategy. In H1 2026, overseas revenue was RMB 348 million, accounting for 45.70% of total revenue. Revenue from US‑China filing projects hit RMB 167 million, up 93.46% YoY and representing 21.87% of core revenue. New domestic orders grew 148.22% YoY and new overseas orders rose 45.96% YoY. This dual-market expansion mitigates risks tied to fluctuations in any single region.
Sustained Innovation Investment : Counter-Cyclical Technology Build-Up and Refined Operations
Industry downturns offer opportunities to strengthen internal competencies. Through challenging industry phases, Medicilon has never paused its technology roadmap. We keep advancing platforms for ADCs, GLP‑1, PROTACs, CGT, oligonucleotides, AOCs, macrocyclic peptides and in vivo CAR‑T, while investing in AI‑driven drug discovery and NAMs (New Approach Methodologies), building technology reserves for next-generation therapeutics.
Beyond technology investment, Medicilon implements streamlined operational management: optimizing workforce structure, rationalizing lab resources and deploying intelligent project scheduling to cap cost growth below revenue growth. In H1 2026, overall gross margin rose 10.36 percentage points YoY to 31.60%, reflecting markedly improved profitability and laying a solid foundation for sustained long-term growth.